Literature DB >> 20818472

Physicians and caregivers: ready and waiting for increased participation in clinical research.

R W Jones1, S Andrieu, S Knox, J Mackell.   

Abstract

Progressive development of pharmacotherapy for Alzheimer's disease (AD) as well as non-pharmacological treatments is critically dependent on the timely recruitment of appropriate subjects for clinical trials. Accordingly, the IMPACT survey sought to determine the level of awareness of clinical trials and the willingness to foster patient involvement/participation in research studies. IMPACT survey participants were recruited via the Internet in equal numbers from 5 European countries-France, Germany, Italy, Spain and the United Kingdom. During April and May 2009, 250 caregivers and 500 physicians who agreed to participate in this market-based survey completed a 30-minute Web-based questionnaire that included items concerning awareness of clinical research and willingness to facilitate participation of AD patients in such research. Awareness of local clinical trials amongst both caregivers (24% overall; range by country, 14% to 34%) and physicians (19% overall; range by country, 13% to 30%) was found to be low in all countries surveyed. In contrast, the willingness of physicians to refer patients to, and caregivers to support their participation in, clinical trials was extremely high (98% and 81%, respectively). These results strongly indicate that physicians and caregivers are ready and waiting to become more involved in clinical research. Initiatives to increase awareness of clinical trials amongst caregivers and physicians and to conduct clinical trials within the geographical area of as many potential participants as possible should result in much more effective patient recruitment to AD clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20818472     DOI: 10.1007/s12603-010-0269-5

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  19 in total

1.  Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R S Doody; J C Stevens; C Beck; R M Dubinsky; J A Kaye; L Gwyther; R C Mohs; L J Thal; P J Whitehouse; S T DeKosky; J L Cummings
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

2.  Recruitment rates in gerontological research: the situation for drug trials in dementia may be worse than previously reported.

Authors:  J Cohen-Mansfield
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Oct-Dec       Impact factor: 2.703

3.  Use of live theater to increase minority participation in Alzheimer disease research.

Authors:  Thomas Fritsch; Kathryn Betts Adams; Darlyne Redd; Tony Sias; Karl Herrup
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Apr-Jun       Impact factor: 2.703

4.  Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?

Authors:  L Robinson; B Vellas; S Knox; K Lins
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

5.  Assessing attitudes and behaviours surrounding Alzheimer's disease in Europe: key findings of the Important Perspectives on Alzheimer's Care and Treatment (IMPACT) survey.

Authors:  R W Jones; J Mackell; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

6.  Evolving attitudes to Alzheimer's disease among the general public and caregivers in Europe: findings from the IMPACT survey.

Authors:  M Wortmann; S Andrieu; J Mackell; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

7.  Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease.

Authors:  Patrick Griffith; Peter Lichtenberg; Robert Goldman; Jennifer Payne-Parrish
Journal:  J Natl Med Assoc       Date:  2006-10       Impact factor: 1.798

8.  Carer impressions of participation in Alzheimer's disease clinical trials: what are their hopes? And is it worth it?

Authors:  Maree Mastwyk; Craig W Ritchie; Dina LoGiudice; Karen A Sullivan; Stephen Macfarlane
Journal:  Int Psychogeriatr       Date:  2002-03       Impact factor: 3.878

9.  Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study.

Authors:  Oscar L Lopez; Joan A Mackell; Yijun Sun; Laurent M Kassalow; Yikang Xu; Thomas McRae; Honglan Li
Journal:  J Natl Med Assoc       Date:  2008-11       Impact factor: 1.798

10.  When "no" might not quite mean "no"; the importance of informed and meaningful non-consent: results from a survey of individuals refusing participation in a health-related research project.

Authors:  Brian Williams; Linda Irvine; Alison R McGinnis; Marion E T McMurdo; Iain K Crombie
Journal:  BMC Health Serv Res       Date:  2007-04-26       Impact factor: 2.655

View more
  9 in total

1.  Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

2.  The time has arrived to meet the challenge of Alzheimer's disease in Europe.

Authors:  R W Jones
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

3.  Attitudes of small animal practitioners toward participation in veterinary clinical trials.

Authors:  Margaret E Gruen; Emily H Griffith; Sarah M A Caney; Mark Rishniw; B Duncan X Lascelles
Journal:  J Am Vet Med Assoc       Date:  2017-01-01       Impact factor: 1.936

4.  Implications of the Impact Survey for payors across Europe.

Authors:  F Forette; A Padovani; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

5.  Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?

Authors:  L Robinson; B Vellas; S Knox; K Lins
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

6.  Obstacles and opportunities in Alzheimer's clinical trial recruitment.

Authors:  Jennifer L Watson; Laurie Ryan; Nina Silverberg; Vicky Cahan; Marie A Bernard
Journal:  Health Aff (Millwood)       Date:  2014-04       Impact factor: 6.301

7.  Representations and practices of prevention in elderly populations: investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer's disease (ACCEPT study)--the need for a multidisciplinary approach.

Authors:  S Andrieu; N Coley; V Gardette; J Subra; S Oustric; T Fournier; J-P Poulain; D Coniasse-Brioude; V Igier; B Vellas; A Grand
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

Review 8.  Facilitating Alzheimer disease research recruitment.

Authors:  Joshua D Grill; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

Review 9.  Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research.

Authors:  Mercè Boada; Miguel A Santos-Santos; Octavio Rodríguez-Gómez; Montserrat Alegret; Pilar Cañabate; Asunción Lafuente; Carla Abdelnour; Mar Buendía; Maria José de Dios; América Morera; Ángela Sanabria; Laura Campo; Agustín Ruiz; Lluís Tárraga
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.